Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 1;78(2):179–185. doi: 10.1136/annrheumdis-2017-212763

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

(A–F) Changes of B-cell numbers and B-cell related biomarkers. Total number of B cells (Log₁₀ 10⁹/L; A), serum IgA rheumatoid factor (RF) (Log kU/L; B), IgM-RF (Log kU/L; C), IgG-RF (Log kU/L; D); IgM (Log g/L; E), and anti-citrullinated cyclic peptide (CCP) test levels (Log kAU/L; F) from baseline to follow-up time points (days) measured in the individuals treated with placebo (red) and rituximab (green). The thin lines represent changes in the individuals and the thick lines represent the mean numbers/levels for each group. Vertical lines represent the 95% CIs. Statistically significant differences (shown p values) between the two treatment groups were found for all values depicted here, except for the serum IgG-RF and anti-CCP levels.